Business, Health Care

Merck’s KEYTRUDA® (pembrolizumab) reduced the risk of distant metastasis or death by 40% versus placebo as adjuvant treatment in resected, high-risk stage III melanoma

Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer

Business

Wiley mourns the loss of Board Member William Pence

HOBOKEN, N.J.–(BUSINESS WIRE)–It is with great sadness that John Wiley & Sons, Inc. announces the death of Board Member William (Bill) Pence, who passed earlier this month. “Bill was a trusted advisor and a champion of transformation, from culture to tech driven